News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Eisai Company, Ltd. Puts $200 Million into US Personalised Medicine Unit
January 31, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharma Times -- Eisai has formed a biotech start-up in the USA, H3 Biomedecines, which will focus on discovering and developing next-generation cancer drugs.
Twitter
LinkedIn
Facebook
Email
Print
Startups
MORE ON THIS TOPIC
Drug Pricing
BMS, Pfizer Join DTC Trend, Offering Eliquis to Patients for 40% Below List Price
July 17, 2025
·
2 min read
·
Nick Paul Taylor
Layoffs
Sarepta Up 18% After Business Overhaul as Analysts Cautiously Optimistic
July 17, 2025
·
1 min read
·
Heather McKenzie
Tariffs
Novartis ‘Moving as Fast as Possible’ to Fully Manufacture Key Drugs in US as Tariffs Near
July 17, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Sarepta Tags DMD Gene Therapy Elevidys With Black Box Warning, Axes 500 Staff
July 16, 2025
·
2 min read
·
Heather McKenzie
